Rhythm Pharmaceuticals (RYTM) EBT (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly EBT of -$55.1 million for Q1 2026, down 11.49% year-over-year from -$62.2 million in Q1 2025, and down 15.9% quarter-over-quarter from -$47.5 million in Q4 2025.
Powered by 
Analysis
Rhythm Pharmaceuticals (RYTM) EBT (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported EBT for 11 consecutive years, with -$55.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 11.49% year-over-year to -$55.1 million; the TTM figure through Mar 2026 stood at -$201.7 million (down 19.67% YoY), while the FY2025 annual figure was -$196.0 million, up 24.67% from the prior year.
- EBT slipped to -$55.1 million in Q1 2026 per RYTM's latest filing, from -$47.5 million in the prior quarter.
- Across five years, EBT topped out at -$31.8 million in Q2 2024 and bottomed at -$141.1 million in Q1 2024.
- Historically, EBT has averaged -$51.9 million across 5 years, with a median of -$46.7 million in 2023.
- Annual changes were most pronounced in 2022 — EBT tumbled 184.15% — and 2025, when it surged 64.97%.
- Rhythm Pharmaceuticals' EBT stood at -$42.5 million in 2022, then gained by 2.49% to -$41.4 million in 2023, then slipped by 4.69% to -$43.4 million in 2024, then dropped by 9.58% to -$47.5 million in 2025, then slipped by 15.9% to -$55.1 million in 2026.
- Business Quant data shows RYTM's EBT at -$55.1 million in Q1 2026, -$47.5 million in Q4 2025, and -$52.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Rhythm Pharmaceuticals | 7.05 Bn | 6.72 Bn | 62.32 Mn | -48.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -48.85 Mn |
| Mar 31, 2026 | -55.09 Mn |
| Dec 31, 2025 | -47.54 Mn |
| Sep 30, 2025 | -52.79 Mn |
| Jun 30, 2025 | -46.30 Mn |
| Mar 31, 2025 | -49.42 Mn |
| Dec 31, 2024 | -43.38 Mn |
| Sep 30, 2024 | -43.99 Mn |
| Jun 30, 2024 | -31.78 Mn |
| Mar 31, 2024 | -141.07 Mn |
| Dec 31, 2023 | -41.44 Mn |
| Sep 30, 2023 | -43.80 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -44.87 Mn |
| Mar 31, 2022 | -52.53 Mn |
| Dec 31, 2021 | -50.86 Mn |
| Sep 30, 2021 | -44.10 Mn |